Levosimendan bei akuter und chronischer Herzinsuffizienz

Der Kalzium-Sensitizer Levosimendan ist in Deutschland für die Behandlung der akut dekompensierten chronischen Herzinsuffizienz zugelassen. Welchen Stellenwert Levosimendan in der Behandlung der akuten und chronischen Herzinsuffizienz hat, wird in diesem Beitrag anhand aktueller Daten, der Erfahrung eines universitären Herzzentrums sowie ausgewählter klinischer Fallbeispiele erläutert.

• Literatur

• 1 Nieminen MS. et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel 2013; 5: 227-245
• 2 Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-1146
• 3 Crespo-Leiro MG. et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016; 18: 613-625
• 4 Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure?. Europace 2011; 13 (Suppl. 02) 13-17
• 5 Gheorghiade M. et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005; 96: 11G-17G
• 6 Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 2012; 38: 359-367
• 7 Nony P. et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol 1994; 46: 191-196
• 8 Follath F. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202
• 9 McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005; 365: 1877-1889
• 10 McMurray JJ. Improving outcomes in heart failure: a personal perspective. Eur Heart J 2015; 36: 3467-3470
• 11 Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200
• 12 Hochman JS. et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625-634
• 13 Thiele H. et al. Management of cardiogenic shock. Eur Heart J 2015; 36: 1223-1230
• 14 Kivikko M. et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; 40: 465-471
• 15 Mebazaa A. et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891
• 16 Packer M. et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013; 1: 103-111
• 17 Moiseyev VS. et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432
• 18 Fuhrmann JT. et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008; 36: 2257-2266
• 19 Landoni G. et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012; 40: 634-646
• 20 Nieminen MS. et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol 2014; 174: 360-367
• 21 Garcia-Gonzalez MJ. et al. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study. Cardiovasc Drugs Ther 2013; 27: 573-579
• 22 Latva-Hirvela J. et al. Effects of levosimendan in experimental acute coxsackievirus myocarditis. Eur J Clin Invest 2009; 39: 876-882
• 23 Biteker M. et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol 2011; 100: 571-577
• 24 Santoro F. et al. Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: a case series. Cardiovasc Ther 2013; 31: e133-137
• 25 Gordon AC. et al. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med 2016;